首页> 外文期刊>Glia >Elevated GFAP Induces Astrocyte Dysfunction in Caudal Brain Regions: A Potential Mechanism for Hindbrain Involved Symptoms in Type II Alexander Disease
【24h】

Elevated GFAP Induces Astrocyte Dysfunction in Caudal Brain Regions: A Potential Mechanism for Hindbrain Involved Symptoms in Type II Alexander Disease

机译:GFAP升高导致尾脑区域星形胶质细胞功能障碍:II型亚历山大病后脑受累症状的潜在机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Alexander Disease (AxD) is a gliopathy caused by toxic, dominant gain-of-function mutations in the glial fibrillary acidic protein (GFAP) gene. Two distinct types of AxD exist. Type I AxD affected individuals develop cerebral symptoms by 4 years of age and suffer from macrocephaly, seizures, and physical and mental delays. As detection and diagnosis have improved, approximately half of all AxD patients diagnosed have onset >4 years and brainstem/spinal cord involvement. Type II AxD patients experience ataxia, palatal myoclonus, dysphagia, and dysphonia. No study has examined a mechanistic link between the GFAP mutations and caudal symptoms present in type II AxD patients. We demonstrate that two key astrocytic functions, the ability to regulate extracellular glutamate and to take up K+ via K+ channels, are compromised in hindbrain regions and spinal cord in AxD mice. Spinal cord astrocytes in AxD transgenic mice are depolarized relative to WT littermates, and have a three-fold reduction in Ba2+-sensitive Kir4.1 mediated currents and six-fold reduction in glutamate uptake currents. The loss of these two functions is due to significant decreases in Kir4.1 (>70%) and GLT-1 (>60%) protein expression. mRNA expression for KCNJ10 and SLC1A2, the genes that code for Kir4.1 and GLT-1, are significantly reduced by postnatal Day 7. Protein and mRNA reductions for Kir4.1 and GLT-1 are exacerbated in AxD models that demonstrate earlier accumulation of GFAP and increased Rosenthal fiber formation. These findings provide a mechanistic link between the GFAP mutations/overexpression and the symptoms in those affected with Type II AxD.
机译:亚历山大病(AxD)是一种神经胶质病,由神经胶质原纤维酸性蛋白(GFAP)基因中的毒性,显性功能获得性突变引起。存在两种不同类型的AxD。受I型AxD影响的个体到4岁时会出现脑部症状,并患有大头畸形,癫痫发作以及身心延迟。随着检测和诊断的改善,所有诊断出的AxD患者中大约有一半发病> 4年,并累及了脑干/脊髓。 II型AxD患者经历共济失调,pa肌阵挛,吞咽困难和听觉障碍。尚无研究检查GFAP突变与II型AxD患者中存在的尾部症状之间的机制相关性。我们证明了两个关键的星形细胞功能,即调节细胞外谷氨酸和通过K +通道吸收K +的能力在AxD小鼠的后脑区域和脊髓中受到损害。相对于野生型同窝小鼠,AxD转基因小鼠中的脊髓星形胶质细胞去极化,并且Ba2 +敏感的Kir4.1介导电流降低了三倍,而谷氨酸摄取电流降低了六倍。这两个功能的丧失是由于Kir4.1(> 70%)和GLT-1(> 60%)蛋白表达显着下降。出生后第7天,编码Kir4.1和GLT-1的基因KCNJ10和SLC1A2的mRNA表达显着降低。在AxD模型中,Kir4.1和GLT-1的蛋白质和mRNA降低更为严重,这表明AxD模型的早期积累GFAP和增加的Rosenthal纤维形成。这些发现为GFAP突变/过表达与II型AxD感染者的症状之间提供了机械联系。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号